miR‑149‑5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway

Manman Xu(Capital Medical University), Shuzhong Yao(Sun Yat-sen University)
International Journal of Oncology
January 24, 2018
10.3892/ijo.2018.4252
Cited by 53

Related Papers

FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis
|Cell Death and Disease|2022|128
Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer
|Cell Metabolism|2023|44
Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition
|Cancers|2022|10
Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
|Unknown|2023|0
Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
|Unknown|2023|0